Prophylactic granulocyte colony-stimulating factor in the critically ill: Carefully balancing the benefits and risks

Critical Care Medicine

Volumn 30, Issue 9, 2002, Pages 2162-2164

  Quezado, Zenaide M N ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Granulocyte colony stimulating factor; Inflammatory response; Sepsis

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTIFICIAL VENTILATION; BACTERICIDAL ACTIVITY; CELL FUNCTION; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFECTION RISK; INFECTION SENSITIVITY; INTENSIVE CARE; LUNG INJURY; MONOCYTE; NONHUMAN; NUTRITIONAL SUPPORT; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; SEPSIS;

EID: 0036743118     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200209000-00045     Document Type: Editorial

References (27)

1. Freeman BD, Natanson C: Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 2000; 9:1651-1663
2. Natanson C, Hoffman WD, Suffredini AF, et al: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120:771-783
3. Parent C, Eichacker PQ: Granulocyte colony stimulating factor as a therapy for pneumonia and sepsis in the nonneutropenic host: Preclinical and clinical trials. In: Perspectives on Critical Care Infectious Diseases. Vol. 2. Eichacker PQ, Pugin J (Eds). Boston, Kluwer Academic, 2001, pp 175-187
4. Root RK, Dale DC: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: Comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 1999; 179(Suppl 2):S342-S352
5. Nelson S, Summer WR: Innate immunity, cytokines, and pulmonary host defense. Infect Dis Clin North Am 1998; 12:555-567
6. Welte K, Gabrilove J, Bronchud MH, et al: Filgrastim (r-metHuG-CSF): The first 10 years. Blood 1996; 88:1907-1929
7. Esposito C, Banks SM, Eichacker PQ: Prophylactic granulocyte colony-stimulating factor in critically ill patients: Not time yet. Crit Care Med 1998; 26:636-637
8. Quezado Z, Parent C, Karzai W, et al: Acute G-CSF therapy is not protective during lethal E. coli sepsis. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1177-R1185
9. Nelson S, Heyder AM, Stone J, et al: A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 2000; 182:970-973
10. Wunderink R, Leeper K Jr, Schein R, et al: Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 2001; 119:523-529
11. Ishikawa K, Tanaka H, Nakamori Y, et al: Difference in the responses after administration of granulocyte colony- stimulating factor in septic patients with relative neutropenia. J Trauma 2000; 48:814-825
12. Volk HD, Reinke P, Docke WD: Clinical aspects: From systemic inflammation to "immunoparalysis." Chem Immunol 2000; 74:162-177
13. Volk HD, Wolk K, Sabat R, et al: Immunostimulation in sepsis. In: Perspectives on Critical Care Infectious Diseases. Vol. 2. Eichacker PQ, Pugin J (Eds). Boston, Kluwer Academic, 2001, pp 163-174
14. Stephan F, Yang K, Tankovic J, et al: Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 2002; 30:315-322
15. Ahmed NA, McGill S, Yee J, et al: Mechanisms for the diminished neutrophil exudation to secondary inflammatory sites in infected patients with a systemic inflammatory response (sepsis). Crit Care Med 1999; 27:2459-2468
16. Weiss M, Gross-Weege W, Schneider M, et al: Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care 1995; 10:21-26
17. Docke WD, Randow F, Syrbe U, et al: Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat Med 1997; 3:678-681
18. Eichacker PQ, Waisman Y, Natanson C, et al: Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. J Appl Physiol 1994; 77:2366-2373
19. Freeman BD, Quezado Z, Zeni F, et al: rG-CSF reduces endotoxemia and improves survival during E. coli pneumonia. J Appl Physiol 1997; 83:1467-1475
20. Freeman BD, Correa R, Karzai W, et al: Controlled trials of rG-CSF and CD11b-directed MAb during hyperoxia and E. coli pneumonia in rats. J Appl Physiol 1996; 80:2066-2076
21. Karzai W, von Specht BU, Parent C, et al: G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 1999; 159:1377-1382
22. Abraham E, Stevens P: Effects of granulocyte colony-stimulating factor in modifying mortality from Pseudomonas aeruginosa pneumonia after hemorrhage. Crit Care Med 1992; 20:1127-1133
23. Davis KA, Fabian TC, Ragsdale DN, et al: Granulocyte colony-stimulating factor and neutrophil-related changes in local host defense during recovery from shock and intra-abdominal sepsis. Surgery 1999; 126:305-313
24. Heard SO, Fink MP, Gamelli RL, et al: Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group. Crit Care Med 1998; 26:748-754
25. Pettila V, Takkunen O, Varpula T, et al: Safety of granulocyte colony-stimulating factor (filgrastim) in intubated patients in the intensive care unit: Interim analysis of a prospective, placebo-controlled, double-blind study. Crit Care Med 2000; 28:3620-3625
26. Attalah HL, Azoulay E, Yang K, et al: Granulocyte colony-stimulating factor enhances host defenses against bacterial pneumonia following peritonitis in nonneutropenic rats. Crit Care Med 2002; 30:2107-2114
27. Karzai W, Eichacker PQ, Mehlhorn B, et al: The role of neutrophils in ventilation induced lung injury. Anesthesiology 1999; 91:A1394